伊莱克特拉治疗 ETRA
$7.80 +$0.45 (+6.12%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $7.80 0.00%
开盘$7.72
昨收$7.35
当日区间$7.20 – $8.10
成交量401.3K
市值$476.58M
市盈率（TTM）–
股息率–
股权结构与仓位
谁在持有、谁在做空，以及大资金的流向
机构持股比例52.3%+52.27 个百分点，较上季度
持仓机构数12+12 ，较上季度
内部人近期交易6次买入 / 0次卖出净买入
空头持仓比例0.67% 占流通股回补天数 1.0 · 截至 15 Oct 2026
卖空成交量占比11.1%近5日成交量平均占比
卖空成交量占当日成交量比例
大单净流入，近20个交易日
大单买入减卖出的净额（美元）。该窗口期内：+$286.5K（7个净流入日，13个净流出日）。
按单量净流入，近20个交易日
超大单/大单近似机构级别交易；中单/小单近似散户级别交易。各档买入减卖出净额，按窗口期累计。
已披露的前五大股东合计持有41.9%的流通股。
最大股东
按投资者类型
近期机构持仓变动
| 股东 | 类型 | 期间 | 持股变动 | 新持股比例 |
|---|---|---|---|---|
| T. Rowe Price Group, Inc. | Mutual Fund | 2026/Q3 | +417,567 | 0.7% |
| Vanguard Capital Management, LLC | Mutual Fund | 2026/Q3 | +225,156 | 0.4% |
| Columbia Management Investment Advisers, LLC | Mutual Fund | 2026/Q3 | +127,942 | 0.2% |
| Y-Intercept (Hong Kong) Limited | Mutual Fund | 2026/Q3 | +21,103 | 0.0% |
| Vanguard Portfolio Management, LLC | Mutual Fund | 2026/Q3 | +18,205 | 0.0% |
| OrbiMed Advisors LLC | VC/PE Fund | 2026/Q3 | +6,885,170 | 11.0% |
| Westlake Village BioPartners | VC/PE Fund | 2026/Q3 | +6,347,539 | 10.1% |
| Redmile Group, LLC | Hedge Fund | 2026/Q3 | +5,462,881 | 8.7% |
| Lsp 7 Cooperatief U.A. | Private Company | 2026/Q3 | +3,795,281 | 6.0% |
| EQT Life Sciences | VC/PE Fund | 2026/Q3 | +3,795,281 | 6.0% |
| Quehuong Dong | Individual/Insider | 2026/Q3 | +455,484 | 0.7% |
| Nancy Stagliano | Individual/Insider | 2026/Q3 | +255,635 | 0.4% |
| Graham Parry | Individual/Insider | 2026/Q3 | +85,504 | 0.1% |
| Gary Koe | Individual/Insider | 2026/Q3 | +63,656 | 0.1% |
| New Leaf Venture Partners, LLC | VC/PE Fund | 2026/Q3 | +3,248,304 | 5.2% |
按报告期列出的机构买卖动态，变动幅度从大到小排列。
内部人交易
| 日期 | 内部人 | 职位 | 交易类型 | 股数 | 价格 | 交易后持股 |
|---|---|---|---|---|---|---|
| 20 Sep 2026 | OrbiMed Advisors LLC | Private Acquisition | +1,333,333 | $15.00 | 6,885,170 | |
| 20 Sep 2026 | OrbiMed Advisors LLC | Derivative Exercise and Retained | +5,551,837 | – | 6,885,170 | |
| 20 Sep 2026 | Nancy Stagliano | Independent Chairperson | Derivative Exercise and Retained | +255,635 | – | 255,635 |
| 20 Sep 2026 | Graham Parry | Chief Scientific Officer | Derivative Exercise and Retained | +85,504 | – | 85,504 |
| 20 Sep 2026 | Quehuong Dong | Chief Executive Officer | Derivative Exercise and Retained | +455,484 | – | 455,484 |
| 20 Sep 2026 | Westlake Village BioPartners | Initial Statement of Beneficial | +0 | – | 6,347,539 | |
| 20 Sep 2026 | Gary Koe | Chief Technology Officer | Derivative Exercise and Retained | +63,656 | – | 63,656 |
| 17 Sep 2026 | Carl Gordon | Independent Director | Initial Statement of Beneficial | +0 | – | 22,632 |
| 17 Sep 2026 | Matthew Fust | Independent Director | Initial Statement of Beneficial | +0 | – | 159,432 |
| 17 Sep 2026 | David Tucker | Senior VP of Finance & Principal Accounting Officer | Initial Statement of Beneficial | +0 | – | 187,402 |
| 17 Sep 2026 | Nancy Stagliano | Independent Chairperson | Initial Statement of Beneficial | +0 | – | 288,814 |
| 17 Sep 2026 | Graham Parry | Chief Scientific Officer | Initial Statement of Beneficial | +0 | – | 187,402 |
| 17 Sep 2026 | Quehuong Dong | Chief Executive Officer | Initial Statement of Beneficial | +0 | – | 2,298,219 |
| 17 Sep 2026 | Kim-Hien Dao | Chief Medical Officer | Initial Statement of Beneficial | +0 | – | 703,181 |
| 17 Sep 2026 | Gary Koe | Chief Technology Officer | Initial Statement of Beneficial | +0 | – | 548,616 |
数据来自Form 4/Form 144申报文件。负数为减持（出售、赠予或代扣税款股份），正数为增持。
空头持仓（按报告期）
| 报告日期 | 空头股数 | 占流通股比例 | 回补天数 |
|---|---|---|---|
| 15 Oct 2026 | 409,380 | 0.7% | 1.0 |
| 30 Sep 2026 | 702,266 | 1.1% | 1.0 |
暂无评论——快来第一个聊聊 ETRA。